Wall Street Analysts Believe CorMedix (CRMD) Could Rally 142.25%: Here's is How to Trade
The mean of analysts' price targets for CorMedix (CRMD) points to a 142.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CorMedix Inc. (CRMD) Q2 2024 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Joe Todisco - CEO Matt David - EVP and CFO Liz Hurlburt - EVP and Chief Clinical Strategy and Operations Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Jason Butler - Citizens JMP Les Sulewski - Truist John Juco - Needham & Company Operator Good day, and welcome to the CorMedix Inc. Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.
CorMedix (CRMD) Reports Q2 Loss, Tops Revenue Estimates
CorMedix (CRMD) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.25 per share a year ago.
